{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:17:36Z","timestamp":1792513056188,"version":"4.5.0"},"reference-count":161,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Fibroblast growth factor receptors (FGFRs) are a family of receptor tyrosine kinases that are involved in the regulation of cell proliferation, survival, and development. FGFR alterations including amplifications, fusions, rearrangements, and mutations can result in the downstream activation of tyrosine kinases, leading to tumor development. Targeting these FGFR alterations has shown to be effective in treating cholangiocarcinoma, urothelial carcinoma, and myeloid\/lymphoid neoplasms, and there are currently four FGFR inhibitors approved by the Food and Drug Administration (FDA). There have been developments in multiple agents targeting the FGFR pathway, including selective FGFR inhibitors, ligand traps, monoclonal antibodies, and antibody\u2013drug conjugates. However, most of these agents have variable and low responses, with some intolerable toxicities and acquired resistances. This review will summarize previous clinical experiences and current developments in agents targeting the FGFR pathway, and will also discuss future directions for FGFR-targeting agents.<\/jats:p>","DOI":"10.3390\/ijms25020849","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T07:50:48Z","timestamp":1704873048000},"page":"849","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Molecular Targeting of the Fibroblast Growth Factor Receptor Pathway across Various Cancers"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8035-0024","authenticated-orcid":false,"given":"Khine S.","family":"Shan","sequence":"first","affiliation":[{"name":"Memorial Health Care, Division of Hematology and Oncology, Pembroke Pines, FL 33028, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani","family":"Dalal","sequence":"additional","affiliation":[{"name":"Memorial Health Care, Division of Hematology and Oncology, Pembroke Pines, FL 33028, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nyein Nyein","family":"Thaw Dar","sequence":"additional","affiliation":[{"name":"Memorial Health Care, Division of Hematology and Oncology, Pembroke Pines, FL 33028, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omani","family":"McLish","sequence":"additional","affiliation":[{"name":"Memorial Health Care, Division of Hematology and Oncology, Pembroke Pines, FL 33028, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Salzberg","sequence":"additional","affiliation":[{"name":"Memorial Health Care, Division of Hematology and Oncology, Pembroke Pines, FL 33028, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Pico","sequence":"additional","affiliation":[{"name":"Memorial Health Care, Division of Hematology and Oncology, Pembroke Pines, FL 33028, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signalling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"100647","DOI":"10.1016\/j.esmoop.2022.100647","article-title":"Targeting the FGF\/FGFR axis and its co-alteration allies","volume":"7","author":"Uehara","year":"2022","journal-title":"ESMO Open"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.3892\/ol.2020.11858","article-title":"Therapeutic implications of fibroblast growth factor receptor inhibitors in a combination regimen for solid tumors","volume":"20","author":"Luo","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"13509","DOI":"10.1080\/07391102.2023.2191721","article-title":"The FGF\/FGFR signalling mediated anti-cancer drug resistance and therapeutic intervention","volume":"41","author":"Mahapatra","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.2147\/OTT.S282718","article-title":"Targeting FGFR2 Positive Gastroesophageal Cancer: Current and Clinical Developments","volume":"15","author":"Gordon","year":"2022","journal-title":"OncoTargets Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1186\/s13046-021-02156-6","article-title":"Fibroblast growth factor receptor fusions in cancer: Opportunities and challenges","volume":"40","author":"Chen","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10637-019-00783-7","article-title":"A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma","volume":"38","author":"Levchenko","year":"2020","journal-title":"Investig. New Drugs"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/wdev.176","article-title":"The Fibroblast Growth Factor signaling pathway","volume":"4","author":"Ornitz","year":"2015","journal-title":"Wiley Interdiscip. Rev. Dev. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd2792","article-title":"The FGF family: Biology, pathophysiology and therapy","volume":"8","author":"Beenken","year":"2009","journal-title":"Nat. Rev. Drug. Discov."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.gendis.2014.09.005","article-title":"Fibroblast growth factor (FGF) signaling in development and skeletal diseases","volume":"1","author":"Teven","year":"2014","journal-title":"Genes Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41392-020-00222-7","article-title":"FGF\/FGFR signaling in health and disease","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1200\/JCO.2006.09.0795","article-title":"Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas","volume":"25","author":"Birrer","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/bjc.2012.410","article-title":"Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer","volume":"107","author":"Smith","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5878","DOI":"10.1038\/sj.onc.1204755","article-title":"Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer","volume":"20","author":"Steele","year":"2001","journal-title":"Oncogene"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/IGC.0b013e31828f38c4","article-title":"Fibroblast growth factor receptor 2 expression may be involved in transformation of ovarian endometrioma to clear cell carcinoma of the ovary","volume":"23","author":"Taniguchi","year":"2013","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1158\/1078-0432.CCR-12-2736","article-title":"Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer","volume":"19","author":"Zaid","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12967-016-0874-0","article-title":"Expression of fibroblast growth factor receptor family members is associated with prognosis in early stage cervical cancer patients","volume":"14","author":"Choi","year":"2016","journal-title":"J. Transl. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1158\/2159-8290.CD-13-0050","article-title":"Identification of targetable FGFR gene fusions in diverse cancers","volume":"3","author":"Wu","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/hep.26890","article-title":"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma","volume":"59","author":"Arai","year":"2014","journal-title":"Hepatology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00080","article-title":"Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype","volume":"2","author":"Jain","year":"2018","journal-title":"JCO Precis Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1200\/GO.20.00030","article-title":"Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma","volume":"6","author":"Kongpetch","year":"2020","journal-title":"JCO Glob. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10555-015-9579-8","article-title":"Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: Biologic and clinical implications","volume":"34","author":"Helsten","year":"2015","journal-title":"Cancer Metastasis Rev."},{"key":"ref_24","first-page":"3893","article-title":"Comprehensive identification of FGFR1-4 alterations in 5 557 Chinese patients with solid tumors by next-generation sequencing","volume":"11","author":"Gu","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"55924","DOI":"10.18632\/oncotarget.10482","article-title":"FGFR3-TACC3 fusion in solid tumors: Mini review","volume":"7","author":"Costa","year":"2016","journal-title":"Oncotarget"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1126\/science.1220834","article-title":"Transforming fusions of FGFR and TACC genes in human glioblastoma","volume":"337","author":"Singh","year":"2012","journal-title":"Science"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/bjc.2013.802","article-title":"FGFR2 amplification has prognostic significance in gastric cancer: Results from a large international multicentre study","volume":"110","author":"Su","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/bjc.2011.603","article-title":"FGFR2 gene amplification and clinicopathological features in gastric cancer","volume":"106","author":"Matsumoto","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.humpath.2011.12.002","article-title":"Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma","volume":"43","author":"Jung","year":"2012","journal-title":"Hum. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1038\/sj.onc.1210399","article-title":"Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer","volume":"26","author":"Tomlinson","year":"2007","journal-title":"Oncogene"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR Project GENIE: Powering Precision Medicine through an International Consortium","volume":"7","author":"Arnedos","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.eururo.2015.07.039","article-title":"Genomic Characterization of Upper Tract Urothelial Carcinoma","volume":"68","author":"Sfakianos","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/cncr.29826","article-title":"Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations","volume":"122","author":"Ross","year":"2016","journal-title":"Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.2217\/fon-2016-0042","article-title":"A place for precision medicine in bladder cancer: Targeting the FGFRs","volume":"12","author":"Tomlinson","year":"2016","journal-title":"Future Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/path.2207","article-title":"FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer","volume":"213","author":"Tomlinson","year":"2007","journal-title":"J. Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"490","DOI":"10.20892\/j.issn.2095-3941.2020.0120","article-title":"Targeting FGFR in non-small cell lung cancer: Implications from the landscape of clinically actionable aberrations of FGFR kinases","volume":"18","author":"Zhou","year":"2021","journal-title":"Cancer Biol. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.lungcan.2017.07.006","article-title":"Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients","volume":"111","author":"Ou","year":"2017","journal-title":"Lung. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"6652","DOI":"10.1158\/1078-0432.CCR-06-1164","article-title":"FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas","volume":"12","author":"Simpson","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Santolla, M.F., Vivacqua, A., Lappano, R., Rigiracciolo, D.C., Cirillo, F., Galli, G.R., Talia, M., Brunetti, G., Miglietta, A.M., and Belfiore, A. (2019). GPER Mediates a Feedforward FGF2\/FGFR1 Paracrine Activation Coupling CAFs to Cancer Cells toward Breast Tumor Progression. Cells, 8.","DOI":"10.3390\/cells8030223"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1158\/0008-5472.CAN-09-3746","article-title":"FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer","volume":"70","author":"Turner","year":"2010","journal-title":"Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/s41467-019-09068-2","article-title":"Aberrant FGFR signaling mediates resistance to CDK4\/6 inhibitors in ER+ breast cancer","volume":"10","author":"Formisano","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1758835920915305","DOI":"10.1177\/1758835920915305","article-title":"FGFR aberrations increase the risk of brain metastases and predict poor prognosis in metastatic breast cancer patients","volume":"12","author":"Xie","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12964-019-0486-4","article-title":"FGFR3 signaling and function in triple negative breast cancer","volume":"18","author":"Chew","year":"2020","journal-title":"Cell Commun. Signal"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1002\/ijc.26304","article-title":"Mechanisms of FGFR3 actions in endocrine resistant breast cancer","volume":"130","author":"Tomlinson","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1073\/pnas.91.2.484","article-title":"Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas","volume":"91","author":"Yamaguchi","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/BF01328955","article-title":"Basic fibroblast growth factor and fibroblast growth factor receptor I are implicated in the growth of human astrocytomas","volume":"18","author":"Morrison","year":"1994","journal-title":"J. Neurooncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"10231","DOI":"10.1074\/jbc.270.17.10231","article-title":"Alternately spliced NH2-terminal immunoglobulin-like Loop I in the ectodomain of the fibroblast growth factor (FGF) receptor 1 lowers affinity for both heparin and FGF-1","volume":"270","author":"Wang","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1158\/1535-7163.MCT-07-2263","article-title":"EphA4 promotes cell proliferation and migration through a novel EphA4-FGFR1 signaling pathway in the human glioma U251 cell line","volume":"7","author":"Fukai","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1158\/0008-5472.CAN-15-2058","article-title":"FGFR1 Induces Glioblastoma Radioresistance through the PLC\u03b3\/Hif1\u03b1 Pathway","volume":"76","author":"Delmas","year":"2016","journal-title":"Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/(SICI)1097-4547(19960901)45:5<534::AID-JNR3>3.0.CO;2-D","article-title":"Rat oligodendrocytes and astrocytes preferentially express fibroblast growth factor receptor-2 and -3 mRNAs","volume":"45","author":"Miyake","year":"1996","journal-title":"J. Neurosci. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.3892\/or.2014.3283","article-title":"Downregulation of fibroblast growth factor receptor 2 and its isoforms correlates with a high proliferation rate and poor prognosis in high-grade glioma","volume":"32","author":"Ohashi","year":"2014","journal-title":"Oncol. Rep."},{"key":"ref_53","first-page":"789","article-title":"Loss of heterozygosity on chromosome 10q associated with malignancy and prognosis in astrocytic tumors, and discovery of novel loss regions","volume":"12","author":"Daido","year":"2004","journal-title":"Oncol. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1186\/s12967-016-1075-6","article-title":"FGFR1 and NTRK3 actionable alterations in \u201cWild-Type\u201d gastrointestinal stromal tumors","volume":"14","author":"Shi","year":"2016","journal-title":"J. Transl. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1158\/1541-7786.MCR-16-0376","article-title":"Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST","volume":"15","author":"Pantaleo","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1158\/0008-5472.CAN-14-0573","article-title":"Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance","volume":"75","author":"Traer","year":"2015","journal-title":"Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1158\/2159-8290.CD-14-0763","article-title":"FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors","volume":"5","author":"Li","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Boichuk, S., Galembikova, A., Dunaev, P., Valeeva, E., Shagimardanova, E., Gusev, O., and Khaiboullina, S. (2017). A Novel Receptor Tyrosine Kinase Switch Promotes Gastrointestinal Stromal Tumor Drug Resistance. Molecules, 22.","DOI":"10.3390\/molecules22122152"},{"key":"ref_59","first-page":"3395","article-title":"Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models","volume":"119","author":"Taylor","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/ijc.28800","article-title":"FGFR4 signaling couples to Bim and not Bmf to discriminate subsets of alveolar rhabdomyosarcoma cells","volume":"135","author":"Wachtel","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1158\/1078-0432.CCR-16-0860","article-title":"Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma","volume":"23","author":"Chudasama","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1158\/1078-0432.CCR-14-2744","article-title":"Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma","volume":"21","author":"Agelopoulos","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13148-021-01212-4","article-title":"Fibroblast growth factor (FGF), FGF receptor (FGFR), and cyclin D1 (CCND1) DNA methylation in head and neck squamous cell carcinomas is associated with transcriptional activity, gene amplification, human papillomavirus (HPV) status, and sensitivity to tyrosine kinase inhibitors","volume":"13","author":"Bao","year":"2021","journal-title":"Clin. Epigenetics"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"E1646","DOI":"10.1002\/hed.24292","article-title":"Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing","volume":"38","author":"Tillman","year":"2016","journal-title":"Head. Neck."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.3892\/or.2017.5801","article-title":"Targeting VEGFR and FGFR in head and neck squamous cell carcinoma in vitro","volume":"38","author":"Brands","year":"2017","journal-title":"Oncol. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Nayak, S., Goel, M.M., Makker, A., Bhatia, V., Chandra, S., Kumar, S., and Agarwal, S.P. (2015). Fibroblast Growth Factor (FGF-2) and Its Receptors FGFR-2 and FGFR-3 May Be Putative Biomarkers of Malignant Transformation of Potentially Malignant Oral Lesions into Oral Squamous Cell Carcinoma. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0138801"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.1158\/1078-0432.CCR-11-0050","article-title":"Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells","volume":"17","author":"Marshall","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Kim, E.K., Cho, Y.A., Koh, Y.W., Shin, H.A., Cho, B.C., and Yoon, S.O. (2020). Prognostic implications of Fibroblast growth factor receptor 1 (FGFR1) gene amplification and protein overexpression in hypopharyngeal and laryngeal squamous cell carcinoma. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-06792-7"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/1078-0432.CCR-13-3310","article-title":"Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas","volume":"21","author":"Seiwert","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.4161\/15384047.2014.961874","article-title":"Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma","volume":"15","author":"Yuan","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40291-016-0204-5","article-title":"FGFR Family Members Protein Expression as Prognostic Markers in Oral Cavity and Oropharyngeal Squamous Cell Carcinoma","volume":"20","author":"Koole","year":"2016","journal-title":"Mol. Diagn. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.7150\/jca.12825","article-title":"High Expression of FGFR4 Enhances Tumor Growth and Metastasis in Nasopharyngeal Carcinoma","volume":"6","author":"Shi","year":"2015","journal-title":"J. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13045-021-01040-2","article-title":"FGFR-TKI resistance in cancer: Current status and perspectives","volume":"14","author":"Yue","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-19-0631","article-title":"Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma","volume":"19","author":"Krook","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_75","unstructured":"(2023, November 06). Helsinn to Withdraw NDA for Cholangiocarcinoma. Available online: https:\/\/www.fdanews.com\/articles\/209797-helsinn-to-withdraw-nda-for-cholangiocarcinoma."},{"key":"ref_76","unstructured":"FDA (2023, August 27). FDA Grants Accelerated Approval to Pemigatinib for Cholangiocarcinoma with an FGFR2 Rearrangement or Fusion, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pemigatinib-cholangiocarcinoma-fgfr2-rearrangement-or-fusion."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study","volume":"21","author":"Sahai","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1200\/JCO.2021.39.15_suppl.4086","article-title":"Pemigatinib for previously treated locally advanced\/metastatic cholangiocarcinoma (CCA): Update of FIGHT-202","volume":"39","author":"Sahai","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_79","first-page":"TPS592","article-title":"FIGHT-302: Phase III study of first-line (1L) pemigatinib (PEM) versus gemcitabine (GEM) plus cisplatin (CIS) for cholangiocarcinoma (CCA) with FGFR2 fusions or rearrangements","volume":"38","author":"Valle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.2217\/fon-2020-0429","article-title":"FIGHT-302: First-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements","volume":"16","author":"Valle","year":"2020","journal-title":"Future Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1182\/blood-2021-148103","article-title":"A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients with Myeloid\/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLN FGFR1)","volume":"138","author":"Gotlib","year":"2021","journal-title":"Blood"},{"key":"ref_82","unstructured":"FDA (2023, August 27). FDA Approves Pemigatinib for Relapsed or Refractory Myeloid\/Lymphoid Neoplasms with FGFR1 Rearrangement, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pemigatinib-relapsed-or-refractory-myeloidlymphoid-neoplasms-fgfr1-rearrangement#:~:text=On%20August%2026%2C%202022%2C%20the%20Food%20and%20Drug,with%20fibroblast%20growth%20factor%20receptor%201%20%28FGFR1%29%20rearrangement."},{"key":"ref_83","unstructured":"FDA (2023, August 27). FDA Grants Accelerated Approval to Infigratinib for Metastatic Cholangiocarcinoma, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-infigratinib-metastatic-cholangiocarcinoma."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"TPS356","DOI":"10.1200\/JCO.2021.39.3_suppl.TPS356","article-title":"A phase II study of infigratinib in previously treated advanced\/metastatic cholangiocarcinoma with FGFR gene fusions\/alterations","volume":"39","author":"Javle","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1200\/JCO.2021.39.3_suppl.265","article-title":"Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement","volume":"39","author":"Javle","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_86","unstructured":"(2023, August 27). Helsinn Therapeutics\u2014Discontinuation of Truseltiq\u00ae (Infigratinib). Available online: https:\/\/professionals.optumrx.com\/content\/dam\/optum3\/professional-optumrx\/news\/rxnews\/drug-withdrawls\/drugwithdrawal_truseltiq_2022-1117.pdf."},{"key":"ref_87","unstructured":"FDA (2023, August 27). FDA Grants Accelerated Approval to Erdafitinib for Metastatic Urothelial Carcinoma, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S1470-2045(21)00660-4","article-title":"Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: Long-term follow-up of a phase 2 study","volume":"23","author":"Necchi","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_90","unstructured":"(2023, June 11). Janssen Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of BALVERSA\u00ae (Erdafitinib) for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma and Selected Fibroblast Growth Factor Receptor Gene Alterations. Available online: https:\/\/www.jnj.com\/janssen-submits-supplemental-new-drug-application-to-the-u-s-food-and-drug-administration-seeking-full-approval-of-balversa-erdafitinib-for-the-treatment-of-patients-with-locally-advanced-or-metastatic-urothelial-carcinoma-and-selected-fibroblast-growth-factor-receptor-gene-alterations."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"LBA4619","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4619","article-title":"Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt)","volume":"41","author":"Loriot","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41571-023-00836-0","article-title":"THOR provides new data on the efficacy of erdafitinib","volume":"21","author":"Romero","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_95","unstructured":"FDA (2023, August 27). FDA Grants Accelerated Approval to Futibatinib for Cholangiocarcinoma, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-futibatinib-cholangiocarcinoma."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"TPS600","DOI":"10.1200\/JCO.2020.38.4_suppl.TPS600","article-title":"A phase III study of futibatinib (TAS-120) versus gemcitabine-cisplatin (gem-cis) chemotherapy as first-line (1L) treatment for patients (pts) with advanced (adv) cholangiocarcinoma (CCA) harboring fibroblast growth factor receptor 2 (FGFR2) gene rearrangements (FOENIX-CCA3)","volume":"38","author":"Borad","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(19)30412-7","article-title":"Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: A phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Schuler","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1200\/JCO.21.02303","article-title":"FORT-1: Phase II\/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1\/3 mRNA Expression","volume":"41","author":"Sternberg","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41416-018-0334-0","article-title":"Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma","volume":"120","author":"Mazzaferro","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1200\/JCO.2022.40.4_suppl.427","article-title":"Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Interim results from the phase 2 study FIDES-01","volume":"40","author":"Javle","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1200\/JCO.2023.41.6_suppl.501","article-title":"Efficacy and safety of derazantinib (DZB) in patients with metastatic urothelial carcinoma (mUC) with activating FGFR1\/2\/3 genetic aberrations (GA): Results from the phase 1b\/2 FIDES-02 study","volume":"41","author":"Necchi","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_102","unstructured":"(2023, November 18). Available online: https:\/\/Clinicaltrials.gov."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/2159-8290.CD-23-0475","article-title":"RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations","volume":"13","author":"Subbiah","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1158\/1078-0432.CCR-18-1959","article-title":"A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations","volume":"25","author":"Voss","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1158\/2159-8290.CD-19-0555","article-title":"First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma","volume":"9","author":"Kim","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1200\/JCO.2022.40.4_suppl.304","article-title":"A first-in-human phase 1b study of a novel allosteric extracellular FGFR2 inhibitor alofanib in patients with refractory metastatic gastric cancer","volume":"40","author":"Tjulandin","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10637-016-0404-1","article-title":"Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies","volume":"35","author":"Tyulyandina","year":"2017","journal-title":"Investig. New Drugs"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13046-022-02383-5","article-title":"A first-in-human phase 1\/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors","volume":"41","author":"Chan","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.jtho.2019.05.041","article-title":"SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)","volume":"14","author":"Aggarwal","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1200\/JCO.19.02630","article-title":"Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W","volume":"38","author":"Chae","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1038\/s41467-022-30666-0","article-title":"Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer","volume":"13","author":"Coombes","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jhep.2011.09.017","article-title":"Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma","volume":"56","author":"Huynh","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/1078-0432.CCR-19-1164","article-title":"Lucitanib for the Treatment of HR(+)\/HER2(\u2212) Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study","volume":"26","author":"Hui","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Hayashi, H., Makiyama, A., Okumura, N., Yasufuku, I., Saigo, C., Takeuchi, T., Miyazaki, T., Tanaka, Y., Matsuhashi, N., and Murase, K. (2022). Gastric carcinosarcoma with FGFR2 amplification under long-term control with pazopanib: A case report and literature review. BMC Gastroenterol., 22.","DOI":"10.1186\/s12876-022-02432-5"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2147\/OTT.S189391","article-title":"Ponatinib: A novel multi-tyrosine kinase inhibitor against human malignancies","volume":"12","author":"Tan","year":"2019","journal-title":"Onco Targets Ther."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"178ra139","DOI":"10.1126\/scitranslmed.3005414","article-title":"Blockade of Nonhormonal Fibroblast Growth Factors by FP-1039 Inhibits Growth of Multiple Types of Cancer","volume":"5","author":"Harding","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s10637-021-01146-x","article-title":"A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody\u2013drug conjugate, in patients with advanced or metastatic cancer","volume":"39","author":"Kollmannsberger","year":"2021","journal-title":"Investig. New Drugs"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"39861","DOI":"10.18632\/oncotarget.9515","article-title":"Inhibition of FGF\/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039\/GSK3052230","volume":"7","author":"Blackwell","year":"2016","journal-title":"Oncotarget"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1200\/JCO.2019.37.7_suppl.409","article-title":"Fierce-21: Phase II study of vofatmab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC)","volume":"37","author":"Necchi","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1182\/blood.V120.21.4029.4029","article-title":"A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients with Relapsed or Refractory t(4;14)-Positive Multiple Myeloma","volume":"120","author":"Trudel","year":"2012","journal-title":"Blood"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0959-8049(12)72418-8","article-title":"621 a phase I dose-escalation study of MFGR1877S, a human monoclonal anti-fibroblast growth factor receptor 3 (FGFR3) antibody, in patients (pts) with advanced solid tumors","volume":"48","author":"ODonnell","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1200\/JCO.2019.37.15_suppl.4511","article-title":"FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis","volume":"37","author":"Currie","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/S1470-2045(22)00603-9","article-title":"Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): A randomised, double-blind, placebo-controlled, phase 2 study","volume":"23","author":"Wainberg","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1200\/JCO.2021.39.15_suppl.4010","article-title":"FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric\/gastroesophageal junction adenocarcinoma (GC)","volume":"39","author":"Catenacci","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"TPS4164","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4164","article-title":"Trial in progress: Phase 3 study of bemarituzumab + mFOLFOX6 versus placebo + mFOLFOX6 in previously untreated advanced gastric or gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-101)","volume":"40","author":"Smyth","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s11523-019-00670-4","article-title":"First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody\u2013Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer","volume":"14","author":"Kim","year":"2019","journal-title":"Target Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s10020-021-00306-2","article-title":"The cytotoxic conjugate of highly internalizing tetravalent antibody for targeting FGFR1-overproducing cancer cells","volume":"27","author":"Sochacka","year":"2021","journal-title":"Mol. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"5668","DOI":"10.1158\/0008-5472.CAN-18-0757","article-title":"Transcriptomics and Transposon Mutagenesis Identify Multiple Mechanisms of Resistance to the FGFR Inhibitor AZD4547","volume":"78","author":"Kas","year":"2018","journal-title":"Cancer Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.7150\/jca.40531","article-title":"FGF\/FGFR signaling pathway involved resistance in various cancer types","volume":"11","author":"Zhou","year":"2020","journal-title":"J. Cancer"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.eururo.2017.01.021","article-title":"A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma","volume":"71","author":"Wang","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1002\/ijc.30848","article-title":"Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia\/lymphomas","volume":"141","author":"Cowell","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10120-014-0444-1","article-title":"Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells","volume":"19","author":"Grygielewicz","year":"2016","journal-title":"Gastric. Cancer"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"15014","DOI":"10.18632\/oncotarget.14788","article-title":"Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41416-020-01157-0","article-title":"Fibroblast growth factor receptors in cancer: Genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance","volume":"124","author":"Krook","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1158\/1078-0432.CCR-23-1317","article-title":"Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma","volume":"30","author":"Wu","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_137","first-page":"568","article-title":"Mechanisms of acquired resistance to fibroblast growth factor receptor targeted therapy","volume":"2","author":"Lau","year":"2019","journal-title":"Cancer Drug Resist."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"16052","DOI":"10.18632\/oncotarget.14109","article-title":"Inhibition of the fibroblast growth factor receptor (FGFR) pathway: The current landscape and barriers to clinical application","volume":"8","author":"Chae","year":"2017","journal-title":"Oncotarget"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13058-017-0807-8","article-title":"Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2\u2212 breast cancer that had progressed during or after prior endocrine therapy","volume":"19","author":"Musolino","year":"2017","journal-title":"Breast Cancer Res."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41571-018-0115-y","article-title":"Fibroblast growth factor receptors as treatment targets in clinical oncology","volume":"16","author":"Katoh","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1158\/0008-5472.CAN-15-0509","article-title":"Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC","volume":"75","author":"Singleton","year":"2015","journal-title":"Cancer Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/bjc.2014.638","article-title":"mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma","volume":"112","author":"Scheller","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Sobhani, N., Fassl, A., Mondani, G., Generali, D., and Otto, T. (2021). Targeting Aberrant FGFR Signaling to Overcome CDK4\/6 Inhibitor Resistance in Breast Cancer. Cells, 10.","DOI":"10.3390\/cells10020293"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"936952","DOI":"10.3389\/fonc.2022.936952","article-title":"Comprehensive analysis of the prognostic value and immune infiltration of FGFR family members in gastric cancer","volume":"12","author":"Yang","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"e1019","DOI":"10.1002\/cso2.1019","article-title":"A validated mathematical model of FGFR3-mediated tumor growth reveals pathways to harness the benefits of combination targeted therapy and immunotherapy in bladder cancer","volume":"1","author":"Okuneye","year":"2021","journal-title":"Comput. Syst. Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.cell.2017.01.010","article-title":"Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma","volume":"168","author":"Hugo","year":"2017","journal-title":"Cell"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","article-title":"Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1\/PD-L1","volume":"23","author":"Champiat","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"v405","DOI":"10.1093\/annonc\/mdx376.006","article-title":"Predictive biomarkers for hyper-progression (HP) in response to immune checkpoint inhibitors (ICI)\u2014Analysis of somatic alterations (SAs)","volume":"28","author":"Singavi","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1158\/2326-6066.CIR-15-0274","article-title":"Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer","volume":"4","author":"Sweis","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12943-023-01761-7","article-title":"Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF\/FGFR signaling in tumor microenvironment","volume":"22","author":"Ruan","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1158\/2326-6066.CIR-18-0595","article-title":"The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity","volume":"7","author":"Palakurthi","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000505695","article-title":"Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma","volume":"9","author":"Deng","year":"2020","journal-title":"Liver Cancer"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1200\/JCO.2020.38.15_suppl.3606","article-title":"Safety and efficacy of pemigatinib plus pembrolizumab combination therapy in patients (pts) with advanced malignancies: Results from FIGHT-101, an open-label phase I\/II study","volume":"38","author":"Gutierrez","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2021.39.6_suppl.437","article-title":"Derazantinib (DZB) in combination with atezolizumab (AZB) in patients with solid tumors: Results from the dose-finding phase Ib substudy of FIDES-02","volume":"39","author":"Chaudhry","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-14-2329","article-title":"Targeting FGFR Signaling in Cancer","volume":"21","author":"Touat","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Kommalapati, A., Tella, S.H., Borad, M., Javle, M., and Mahipal, A. (2021). FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice. Cancers, 13.","DOI":"10.3390\/cancers13122968"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"S-1","DOI":"10.6004\/jnccn.2008.2001","article-title":"NCCN Task Force Report: Prevention and Management of Mucositis in Cancer Care","volume":"6","author":"Bensinger","year":"2008","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_158","first-page":"111","article-title":"Reversible Macular Lesions in the Setting of Oral Pan-Fibroblast Growth Factor Inhibitor for the Treatment of Bladder Cancer","volume":"2","author":"Prensky","year":"2018","journal-title":"J. Vitr. Dis."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"5619","DOI":"10.1158\/1078-0432.CCR-21-1414","article-title":"Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer","volume":"27","author":"Jogo","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1158\/1535-7163.MCT-19-0957","article-title":"A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate","volume":"19","author":"Akbulut","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.18632\/oncotarget.2987","article-title":"Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer","volume":"6","author":"Chang","year":"2015","journal-title":"Oncotarget"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/2\/849\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:43:31Z","timestamp":1760103811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/2\/849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,10]]},"references-count":161,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["ijms25020849"],"URL":"https:\/\/doi.org\/10.3390\/ijms25020849","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,10]]}}}